2,439 results on '"Rosell, R"'
Search Results
152. A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
153. PD2.03 Exploration of Factors Relating to Immune Response in Patients Treated with Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (NSCLC)
154. P2.25 Immunotherapy at Any Line of Treatment Improves Survival in Hispanic Patients with Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC) Compared with Chemotherapy (Quijote-CLICaP)
155. PD2.06 EGFR Inhibitors + Bevacizumab Demonstrated Superior Efficacy Compared with EGFR Inhibitors Alone as First-line Treatment in Advanced NSCLC Patients with EGFR Mutations and BIM Deletion Polymorphisms
156. P2.23 Characterization of Hispanic Patients Who Experienced Hyperprogression During Treatment for Advanced NSCLC with Immunotherapy
157. P1.12 Real World Characterization and Treatment Patterns of Patients with Thymic Carcinoma: Lessons from a Latin American Collaborative Study (CLICaP-LATimus)
158. Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations
159. PD1.05 Relevance of Antibiotic Use on Clinical Activity of Immune Checkpoint Inhibitors in Hispanic Patients with Advanced Non-small-cell Lung Cancer (CLICAP-ABs)
160. P2.22 Immunotherapy-related Thrombosis: Considerations and Associated Factors in Non-small Cell Lung Cancer (NSCLC) Patients
161. I.19 New Insights of EGFR Inhibition: How to Overcome Resistance & New Agents
162. Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
163. P1.10 Survival of Thymoma Is Extensive in Latin-American Patients: Results from over 10 Years of Experience (CLICaP-LATimus)
164. Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)
165. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer
166. Incubation of crustacean eggs in vitro
167. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
168. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
169. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer
170. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study
171. Angiotensin AT2-receptor induced interleukin-10 attenuates neuromyelitis optica spectrum disorder-like pathology
172. EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer - preliminary data on safety and tolerability
173. Reccurrence Pattern After Adjuvant Customized Chemotherapy Based on BRCA Expression Level (SCAT Trial)
174. Increased ROS1 and RET Transcripts in Fusion-Negative NSCLC Patients
175. Scientific Mentorship: What Should You Expect?
176. Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
177. mRNA Expression Level of Receptor Tyrosine Kinases and Non-Receptor Tyrosine Kinases as a Recurrence Risk in Resected Adenocarcinoma of the Lung
178. A Single-Center Retrospective Study of Patients with Double Primary Cancers: Breast Cancer and EGFR-Mutant Non-Small Cell Lung Cancer
179. BRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy: SCAT Trial
180. Immunotherapy at Any Line Improves Survival in Hispanic Patients with Advanced Metastatic NSCLC Compared to Chemotherapy (Quijote-CLICaP)
181. Real World Characterization and Treatment of Patients with Thymic Carcinoma: Lessons from a Latin-American Study (CLICaP-LATimus)
182. EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients
183. PKC iota-PAK1 Pathway Modulates Sensitivity to Therapy in EGFR, KRAS Mutant Adenocarcinoma and Squamous Cell Carcinoma
184. HLA-E and FAT1 in Head and Neck and Lung Cancer. The Effect of Osimertinib or Olmutinib with Artesunate (Dihydroartemisinin)
185. KRAS gene status in gastric signet-ring cell carcinoma patients and act as biomarker of MEK inhibitor
186. Anti-EGF antibodies generated by vaccination significantly improve the activity of kinase inhibitors in preclinical models
187. Sensitivity and Optimal Clinicopathological Features of Genetic Targeted Liquid Biopsy in pN0M0 Lung Adenocarcinoma
188. Comprehensive characterization of MET alterations in a large cohort of 610 advanced non-small cell lung cancer patients
189. Osimertinib and dihydroartemisinin: A novel drug combination targeting head and neck squamous cell carcinoma
190. High Rate of Immune Related Pneumonitis in Lung Cancer Patients Treated with Anti PD-1 Antibodies
191. BRAF Mutations: Classes I, II and III in NSCLC Patients Included in the SLLIP Trial, Targeted Treatment According to Class
192. Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: A systematic literature review and pooled-data analysis
193. EGFR Inhibitors Plus Bevacizumab Are Superior Compared to EGFR Inhibitor Monotherapy in Advanced EGFR plus NSCLC Patients with BIM Deletions
194. Copy Number Gains (CNGs) of Clinically Relevant Genes in Advanced NSCLC Patients
195. Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer
196. Survival of Thymoma Is Extensive in Latin-American Patients: Results from Over 10 Years of Experience (CLICaP-LATimus)
197. Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines
198. Targeting PKC iota-PAK1 in EGFR-mutation positive non-small cell lung cancer
199. PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around
200. Association Between Liquid Biopsy and Prognosis of Gastric Cancer Patients: A Systematic Review and Meta-Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.